Loading...
XKRX
096530
Market cap876mUSD
Apr 30, Last price  
26,300.00KRW
1D
-0.75%
Jan 2017
-24.75%
IPO
-32.33%
Name

Seegene Inc

Chart & Performance

D1W1MN
P/E
P/S
3.01
EPS
Div Yield, %
2.28%
Shrs. gr., 5y
-2.28%
Rev. gr., 5y
27.71%
Revenues
414.25b
+12.76%
51,712,796,63058,992,832,19064,410,877,29065,136,597,35773,693,589,45888,919,576,022102,264,773,396121,953,286,8751,125,215,548,2201,370,833,012,026853,561,091,243367,375,048,980414,251,733,220
Net income
-20.34b
L
9,102,938,4159,572,517,8609,141,388,0906,774,128,6017,122,595,5823,186,975,04510,098,321,71226,672,069,051502,281,109,100536,558,868,440182,138,620,710669,011,750-20,336,849,160
CFO
85.39b
-10.05%
3,672,940,358-2,893,225,7806,777,155,7004,104,835,65416,557,316,93710,115,432,38814,009,661,69532,643,051,696383,157,253,783334,024,477,480319,008,873,80594,932,061,45085,390,804,870
Dividend
Sep 27, 2024200 KRW/sh
Earnings
May 08, 2025

Profile

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of six SNPs in factor II, factor V, and MTHFR genes; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy, H&E slides, and paraffin-embedded tissues; Apolipoprotein E genotypes; and BCR/ABL fusion gene from blood and whole bone marrow. In addition, it offers PCR machines; vial cap management systems; nucleic acid extraction systems; automated liquid handling workstations from nucleic acid extraction to PCR setup; and real-time PCR detection systems. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
IPO date
Sep 10, 2010
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
414,251,733
12.76%
367,375,049
-56.96%
853,561,091
-37.73%
Cost of revenue
314,445,049
325,513,957
570,592,101
Unusual Expense (Income)
NOPBT
99,806,685
41,861,092
282,968,991
NOPBT Margin
24.09%
11.39%
33.15%
Operating Taxes
10,844,589
(2,146,624)
43,127,067
Tax Rate
10.87%
15.24%
NOPAT
88,962,096
44,007,715
239,841,924
Net income
(20,336,849)
-3,139.83%
669,012
-99.63%
182,138,621
-66.05%
Dividends
(36,923,149)
(38,075,665)
(51,111,567)
Dividend yield
3.50%
3.53%
3.70%
Proceeds from repurchase of equity
(2,448,886)
(89,875,605)
(70,408,409)
BB yield
0.23%
8.32%
5.10%
Debt
Debt current
94,848,681
94,559,588
100,721,154
Long-term debt
115,812,935
111,678,788
58,464,245
Deferred revenue
511,097
294,100
56,295,852
Other long-term liabilities
12,595,834
11,320,213
11,405,074
Net debt
(103,894,569)
(391,300,988)
(522,076,804)
Cash flow
Cash from operating activities
85,390,805
94,932,061
319,008,874
CAPEX
(39,993,641)
(25,153,769)
(72,451,621)
Cash from investing activities
34,668,575
(278,326,845)
(103,980,105)
Cash from financing activities
(63,704,539)
(156,700,106)
(144,501,126)
FCF
150,035,315
105,545,395
341,256,590
Balance
Cash
522,612,511
520,842,026
603,776,324
Long term investments
(208,056,327)
76,697,339
77,485,879
Excess cash
293,843,598
579,170,612
638,584,148
Stockholders' equity
1,093,887,743
1,152,736,750
1,198,627,916
Invested Capital
841,483,106
604,606,554
678,100,362
ROIC
12.30%
6.86%
35.15%
ROCE
8.77%
3.54%
21.48%
EV
Common stock shares outstanding
46,329
47,147
50,788
Price
22,800.00
-0.44%
22,900.00
-15.81%
27,200.00
-55.41%
Market cap
1,056,293,608
-2.17%
1,079,673,926
-21.84%
1,381,420,898
-56.28%
EV
955,249,305
691,071,062
861,851,652
EBITDA
170,976,580
107,525,888
340,892,253
EV/EBITDA
5.59
6.43
2.53
Interest
5,800,457
6,219,428
5,445,177
Interest/NOPBT
5.81%
14.86%
1.92%